Navigation Links
New treatment option in development for individuals with food allergy
Date:6/25/2014

New Rochelle, NY, June 25, 2014For some children an allergic reaction to common foods such as milk, eggs, or peanuts can cause an anaphylactic reaction. At present no effective treatment for food allergy exists, and strict dietary avoidance of known food triggers is the only preventive option available. Ongoing trials are exploring options for oral immunotherapy (OIT) for desensitization in the treatment of Immunoglobulin E (IgE)-mediated food allergy, as described in a Review article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Pediatric Allergy, Immunology, and Pulmonology website.

In "Oral Immunotherapy for Treatment of Immunoglobulin E-Mediated Food Allergy: The Transition to Clinical Practice," Giovanni Pajno, MD and coauthors, University of Messina, Italy and Nova Southeastern University, Fort Lauderdale, FL, review the current state of OIT research for the induction of tolerance in individuals with food allergies. While early trials with OIT appear promising, rigorous, multicenter, randomized, placebo-controlled studies are needed to address remaining questions regarding optimal formulation, dosing, and duration for the induction of tolerance in affected patients.

"Oral immunotherapy for the treatment of IgE-mediated food allergy remains experimental with a number of unanswered questions," says Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook (Stony Brook, NY) and practicing pediatric pulmonologist at Winthrop University Hospital. "However, it offers the potential for not only a life-saving but life-changing therapy f
'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New treatment option in development for individuals with food allergy
(Date:2/28/2015)... 2015 Plugin creators from Pixel Film ... A fully customizable transition pack made specifically ... gives users total control over 30 transition presets built ... Pixel Film Studios. “TransFold Volume 2 gives endless possibilities ... Volume 2 from Pixel Film Studios brings back folding ...
(Date:2/28/2015)... 28, 2015 The World Scout League ... materials to potential EMTs and firefighters, recently announced its ... a way to raise charitable donations for age-related research. ... Columbia, will be held on March 29, 2015; registration ... begin at 3:30 p.m. , To participate in ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
(Date:2/27/2015)... February 27, 2015 Wireless Analytics, ... services, and one of the founders of ... for Bell Mobility within their CLEAN Platform™ (Communications ... Wireless Analytics’ newly developed Bell Mobility Data ... the Canadian wireless carrier’s business customers. , Wireless ...
(Date:2/27/2015)... A new study published in the Journal of ... on a regular basis and prostate cancer. While cycling is ... more hours per week a man spends cycling, the more ... increased importance on prostate cancer screening methods. , “This study ... at patents’ risk factors for developing prostate cancer,” says Kia ...
Breaking Medicine News(10 mins):Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3
... a novel medical,humidifier, received 510(k) clearance from the ... marketed by PARI Innovative Manufacturers,for ventilator applications. PARI ... compressors, developed the PARI,Hydrate to revolutionize the way ... reduce contamination risk for patients and give clinicians ...
... heroes fighting for treatment, ARLINGTON, Va., Dec. ... Advocacy Center today announced that Karen,Gherardini (Illinois), Janice ... annual Torrey Advocacy Commendation. The,Treatment Advocacy Center (TAC) ... to the timely and effective treatment of,severe mental ...
... Pennsylvania School of Veterinary Medicine have demonstrated the ... the cellular machinery, disrupts normal cellular function and ... for the first time that mitochondria, the cellular ... fuel, are the target of tetrachlorodibenzodioxin, or TCDD. ...
... the removal of cancer involving the tonsil region, according ... of OtolaryngologyHead & Neck Surgery, one of the JAMA/Archives ... patients with cancer through the mouth have limited access ... article. If the cancer has spread to any of ...
... Members ... -, SANTA FE, ... organization, which will help,support the needs of more than 4,000 New Mexico National ... mountain market at,TriWest, will present the check to the Adjutant General of the ...
... VICTORIA, BC, Dec. 17 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation ... that Aspreva,s,shareholders and optionholders have approved the proposed ... a wholly-owned Canadian,subsidiary, at a price of US$26.00 ... securityholders held this morning, the transaction was approved,by ...
Cached Medicine News:Health News:PARI Hydrate Receives FDA Clearance 2Health News:Treatment Advocacy Center Honors Three Grassroots Mental Illness Advocates 2Health News:Agent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research team 2Health News:Robotic device appears useful for surgical removal of cancer involving the tonsils 2Health News:TriWest Contributes $15,000 to New Mexico National Guard Fund 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 3Health News:Aspreva obtains shareholder approval for acquisition by Galenica 4
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the fourth quarter and full year ended December 31, ... for PTC. We are now a growing commercial-stage biopharma ... the rare disease space," stated Stuart W. Peltz, Ph.D., ... to bring the first treatment for Duchenne muscular dystrophy ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... May 14, 2012  Synthetic Biologics, Inc. (NYSE Amex: ... and innovative disease-modifying medicines for serious illnesses, announced today ... President of Clinical & Regulatory Affairs. In this position, ... implementation of all aspects of clinical development, including clinical ...
... GSK (NYSE: GSK ) company, today announced that the ... for Fabior (tazarotene) Foam, 0.1%. It is ... of acne vulgaris in patients 12 years of age and older.  ... patients and dermatologists and we believe Fabior Foam will ...
Cached Medicine Technology:Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 2Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 3Stiefel receives US FDA approval of Fabior™ Foam, 0.1% 2Stiefel receives US FDA approval of Fabior™ Foam, 0.1% 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: